Beam Therapeutics Inc. Marketable Securities (Current)
Beam Therapeutics Inc. (BEAM) had Marketable Securities (Current) of $933.10 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-04
- 2026-06-30: Marketable Securities, Current $933.10M.
- 2026-03-31: Marketable Securities, Current $923.36M.
- 2025-12-31: Marketable Securities, Current $950.27M.
- 2025-09-30: Marketable Securities, Current $807.01M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $933.10M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $923.36M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $950.27M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $807.01M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $868.21M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $692.04M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $568.77M 10-K · filed 2026-02-24 |
| 2024-09-30 | $695.55M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $715.40M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $806.71M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $753.98M 10-Q · filed 2024-11-05 |
| 2023-09-30 | $846.41M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $847.47M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $809.70M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $845.37M 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |